This is an experimental study designed to measure the effect of celecoxib or minocycline on depressive symptoms in unipolar and bipolar depression. Participants will be equally randomized to either celecoxib or minocycline. All participants will complete a battery of clinical and psychological assessments prior to treatment assignment, and again after treatment completion, to assess any changes or improvements in depression.

开始日期2026-01-01

申办/合作机构

Stony Brook University

NCT05367362

/ Not yet recruiting临床2期IIT

Efficacy of Minocycline in Improving Neurological Outcomes of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke

The study will be a prospective, randomized, double- blinded placebo, single center pilot clinical trial. Patients with acute ischemic stroke due to large vessel occlusion undergoing endovascular thrombectomy will be included. The treatment group will receive 200 mg intravenous/oral minocycline hydrochloride in addition to endovascular thrombectomy for a total of 21 days. The control group will receive standard medical and endovascular care along with a similar looking placebo. Patients will be randomized to the treatment or control group by the Pharmacy eliminating the selection bias. The patient and evaluator will be blind to the allocation of patients further minimizing the bias. Through randomization we expect to achieve two groups that are comparable in their baseline clinical characteristics.

开始日期2025-12-01

申办/合作机构

State University of New York at Buffalo

NCT07082855

/ Not yet recruiting临床3期IIT

A Multicenter, Double-Blind, Randomized Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa

This is a multicenter, double-blind, randomized controlled clinical trial to get high - level evidence on minocycline's efficacy and safety?100mg/d, 200mg/d) for Retinitis pigmentosa and to find the optimal treatment dose.

开始日期2025-07-15

申办/合作机构

中山大学中山眼科中心

100 项与盐酸米诺环素相关的临床结果

登录后查看更多信息

100 项与盐酸米诺环素相关的转化医学

登录后查看更多信息

100 项与盐酸米诺环素相关的专利（医药）

登录后查看更多信息

7,275

项与盐酸米诺环素相关的文献（医药）

2025-12-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Protective effects of minocycline on dermal fibroblast cells from oxidant and apoptotic effects of H2O2: A comprehensive analysis with Raman spectroscopy and data-driven approach

Article

作者: Celik, Nusret ; Onses, Mustafa Serdar ; Sahin, Furkan ; Sezer, Gulay

Minocycline (Mino) is an antibiotic with neuroprotective, anti-inflammatory, and antioxidant properties. This study investigated the protective effects of Mino against hydrogen peroxide (H₂O₂)-induced oxidative damage in dermal fibroblast cells and analyzed these effects using Raman spectroscopy, principal component analysis (PCA), and machine learning (ML). L929 fibroblast cells were evaluated using MTT and scratch wound-healing assays. The production of reactive oxygen species (ROS) and the process of apoptosis were evaluated through the use of 2',7'-dichlorofluorescein diacetate (DCFH-DA) and Annexin V labelling, respectively. The mRNA expression levels of Nrf2, Hmox1, Nqo1, and Col1a were analyzed through quantitative real-time polymerase chain reaction (qRT-PCR). Raman spectroscopy detected molecular alterations, while PCA and ML classified spectral variations. Mino reduced H₂O₂-induced cellular toxicity, ROS levels, and apoptosis while enhancing fibroblast migration. It significantly upregulated Nrf2 and Hmox1 mRNA under oxidative stress and increased Col1a expression when applied alone. Raman spectroscopy revealed biochemical changes in lipids, proteins, and nucleic acids. PCA distinguished treatment groups, showing Mino-treated cells closely resembled controls. The SVM attained 90.10 % classification accuracy, underscoring the efficacy of Raman-based computational analysis. The findings collectively highlight the potential of Raman spectroscopy, PCA, and ML as a sensitive, label-free approach for monitoring molecular changes, thereby supporting the therapeutic potential of Mino in oxidative stress-related therapies.

2025-12-01·TOXICOLOGY

A mechanistically-anchored and human stem cell-based in vitro test battery for assessing liver steatogenic potential of chemicals

Article

作者: De Kock, Joery ; Rodrigues, Robim M ; Sanz-Serrano, Julen ; Verhoeven, Anouk ; Gatzios, Alexandra ; Vinken, Mathieu ; Vanhaecke, Tamara

Fatty liver disease, which can result from various factors including chemical exposure, is an increasing clinical concern. A key event in its development is steatosis, referring to the accumulation of lipids within hepatocytes. To enable early detection of chemical-induced liver steatosis, we developed a mechanistically-anchored, human-relevant new approach methodology (NAM). This NAM consists of a 2-tiered in vitro test battery, aligned with the adverse outcome pathway (AOP) network for steatosis, and utilizes human skin-derived precursor cells differentiated into hepatic cells (hSKP-HPC), previously shown to be responsive to steatogenic triggers. In total, 6 well-known steatogenic compounds, including 3 pharmaceuticals (sodium valproate, tetracycline hydrochloride, amiodarone hydrochloride), a pesticide (cyproconazole), and 2 plasticizers (tricresyl phosphate and perfluorohexanesulfonic acid) alongside 2 non-steatogenic chemicals (minocycline hydrochloride and tartaric acid), were tested over a 72-hour period. Tier 1 evaluated transcriptional changes in key lipid metabolism pathways, and modulations were observed in nuclear receptors (peroxisome proliferator-activated receptor), fatty acid uptake (fatty acid translocase), de novo lipogenesis (diacylglycerol acyl transferase 2, fatty acid synthase and stearoyl-CoA desaturase 1), as well as in VLDL secretion (apolipoprotein B100). Tier 2 assays assessed and confirmed downstream functional disruptions in fatty acid uptake and lipid accumulation as ultimate specific key events for steatogenic chemicals. Overall, this human stem cell-based NAM offers a promising tool for supporting early hazard identification of steatogenic chemicals across diverse sectors, bridging mechanistic insights to outcomes relevant to the initiation of fatty liver disease.

2025-12-01·MOLECULAR BIOLOGY REPORTS

Prevalence of New Delhi Metallo-β-lactamase (blaNDM) gene in a selected population of drug-resistant clinical isolates

Article

作者: Ahmed, Iftikhar ; Ahmad, Aftab ; Saeed, Muhammad ; Shafiq, Muhammad ; Latif, Kunza ; Hyder, Muhammad Zeeshan

OBJECTIVES:

Drug-resistant Enterobacterales carrying carbapenem-resistant genes cause severe infections in clinical settings worldwide. Among these, the New Dehli Metallo-β-lactamase (bla_NDM) gene is significantly prevalent and associated with high morbidity. This study was designed to investigate the susceptibility profiling of Carbapenem-Resistant-Enterobacterales (CRE), prevalence of bla_NDM and its variants, and associated risk factors.

METHODS:

CRE isolates from a tertiary care hospital, in Islamabad, Pakistan, were identified and the susceptibility testing was performed using disc diffusion method. MICs were determined for imipenem, tigecycline, and colistin through E-strips and microbroth dilution method respectively. For molecular characterization and typing of the bla_NDM gene, PCR products were sequenced, and the phylogenetic analysis was performed using MEGA ver 6.0 software.

RESULTS:

Among 5,134 clinical samples, 42.13% (n = 2,163) yielded pathogens including 42.58% (n = 921) Enterobacterales. On further screening, 39.52% (n = 364) of Enterobacterales were identified as CRE. The bla_NDM gene was detected in 75.27% (n = 274) in CRE isolates, comprising bla_NDM-1 (44%), bla_NDM-5 (53%), and bla_NDM-7 (3%) variants. Tigecycline (86.7%) and colistin (100%) were most effective antimicrobial agents with MICs ranging from 0.064 to 8 and 0.125-1 µg/ml respectively. bla_NDM-1-harboring bacteria exhibited high antimicrobial resistance compared to bla_NDM-5 and bla_NDM-7. Cefiderocol was 75.6% and ceftazidime/avibactam with aztreonam was 97.08% effective against bla_NDM-harboring bacteria. The phylogenetic analysis indicated that bla_NDM variants showed close genetic relationships and homology to the previously described sequences in GenBank databases having diverse connection with worldwide sequences.

CONCLUSION:

The high prevalence of bla_NDM in our study has of great concern for clinical practice and public health. Clinicians are left with few therapeutic options. However, ceftazidime/avibactam with aztreonam may show therapeutic success. Continuous surveillance is crucial to monitorgenetic variations of continuously evolving bla_NDM gene, which is essential for effective clinical management.

161

项与盐酸米诺环素相关的新闻（医药）

2025-08-20

·摩熵医药

22款新药IND获批，TOP10研发进展大揭秘！恒瑞、礼来等多家药企喜讯频传

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 PART 01 周报概述随着全球医药行业的快速发展，新药研发与创新已成为推动行业进步的重要动力。近期，根据摩熵医药数据统计，新药申请与审批获批频繁，显示出医药创新领域的活跃态势。本文将深入分析2025年8月11日至2025年8月17日期间，国内外新药申请、临床试验批准、仿制药一致性评价等多个方面的最新进展，为用户提供全面的行业资讯。 PART 02 国内22款新药IND获批根据摩熵医药数据库统计，2025年8月11日至8月17日期间共有76个创新药/改良型新药临床申请/上市申请获国家药品监督管理局药品审评中心（CDE）承办（按受理号统计，不含补充申请）。其中国产药品受理号52个，进口药品受理号24个。本周共计22款创新药/改良型新药临床试验申请获得“默示许可”，包括化学药8款，生物药13款，中药1款。本周获批临床创新药/改良型新药部分信息速览（不含补充申请）注：完整数据可识别“文末”二维码下载查看 PART 03 本周全球TOP10创新药研发进展在全球创新药研发领域，8月12日，恒瑞医药宣布其自主研发的1类新药海曲泊帕乙醇胺片的药品上市许可申请获中国国家药监局（NMPA）受理，适应症为：适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的原发免疫性血小板减少症（ITP）成人及≥6岁的儿童患者。海曲泊帕乙醇胺片是一种口服非肽类血小板生成素受体激动剂，通过激活血小板生成素受体介导的STAT和MAPK信号转导通路，促进血小板生成。该产品已在原发免疫性血小板减少症、再生障碍性贫血、化疗所致血小板减少症、有创性操作或手术的慢性肝病伴血小板减少症患者中开展临床研究，以评估在不同血液系统疾病中的作用。截图来源：摩熵医药全球药物研发数据库海曲泊帕乙醇胺片已获批上市两个适应症，分别为：2021年6月获得NMPA批准用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症成人患者的治疗，以及用于对免疫抑制治疗疗效不佳的重型再生障碍性贫血成人患者的治疗。此外，该产品用于恶性肿瘤化疗所致血小板减少症适应症（CIT）已获美国FDA授予孤儿药资格。 8月15日，国家药品监督管理局（NMPA）药品审评中心（CDE）官网显示，礼来的塞普替尼新适应症上市申请已获受理。根据其注册性临床研究进展，推测此次申报的适应症为治疗RET基因融合的局部晚期或转移性实体瘤儿童患者。截图来源：摩熵医药全球药物研发数据库塞普替尼是一种强效、高选择性、口服RET酪氨酸激酶抑制剂，该药于2020年5月首次获FDA批准上市，成为全球首个获批的高选择性RET抑制剂。一项评估塞普替尼治疗携带RET基因改变的晚期实体瘤或神经系统原发性肿瘤儿科患者的疗效和安全性的I/II期研究（LIBRETTO-121研究）最新结果显示，中位随访30个月，在可评估患者（n=36）中，ORR为36%，24个月的DOR率为100%，24个月的PFS率为86%。其中，在15例RET突变型甲状腺髓样癌患者中，ORR为40%；在15例RET融合阳性甲状腺状癌患者中，ORR为33.3%。同样在8月15日，据CDE官网公示，神济昌华申报的1类新药SNUG01获批临床，拟开发治疗肌萎缩侧索硬化（ALS，俗称“渐冻症”），这是神济昌华自主研发的以TRIM72为靶点的基因治疗药物。（相关扩展阅读：全球首创渐冻症基因治疗药获批临床！中国创新药迈入国际赛道）本周全球TOP10创新药研发进展截图来源：摩熵咨询周报 PART 04 本周全球TOP10临床试验结果本周全球TOP10临床结果中，8月12日，默沙东宣布帕博利珠单抗（Keytruda）联合维恩妥尤单抗（Padcev）围手术期治疗肌层浸润性膀胱癌（MIBC）的III期KEYNOTE-905（EV-303）研究取得了积极结果。 KEYNOTE-905（EV-303）研究是一项开放标签、随机、多臂、对照临床试验（n=595），评估了帕博利珠单抗联合或不联合维恩妥尤单抗对比与仅手术治疗在不适合或拒绝基于顺铂的化疗方案的MIBC患者中的有效性和安全性。结果显示，与仅手术治疗组相比，帕博利珠单抗联合维恩妥尤单抗组患者的无事件生存期（EFS）显著延长，数据具有统计学意义和临床意义。此外，帕博利珠单抗联合维恩妥尤单抗组在关键次要终点总生存期（OS）和病理完全缓解（pCR）率方面也表现出具有统计学意义和临床意义的改善。在该研究中，帕博利珠单抗联合维恩妥尤单抗的安全性与每种药物的已知安全性一致。该联用方案未发现新的安全性信号。 8月13日，2025年世界肺癌大会（WCLC 2025）常规摘要正文发布。正大天晴在大会上首次公布了HER2双抗ADC产品TQB2102治疗非小细胞肺癌（NSCLC）的 II 期临床研究数据。截图来源：摩熵医药全球药物研发数据库 TQB2102是一款HER2双抗ADC，采用双表位设计，通过同时结合HER2阳性肿瘤细胞表面的ECD2、ECD4，增强药物内化效率，提升对肿瘤细胞的杀伤作用。此次在大会上公布的II期研究旨在评估 TQB2102在至少接受过一线治疗的局部晚期或转移性HER2基因异常 NSCLC 患者中的疗效。结果显示，在51例可评估疗效的患者中，32例（62.7%）达到部分缓解。队列1（22/36）的ORR为61.1%、队列 2（4/9）的ORR为44.4%、队列3（6/6）的ORR为100%。在32名应答的受试者中，有23名早在第一次肿瘤评估时就观察到了应答。本周全球TOP10积极/失败临床结果截图来源：摩熵咨询周报 PART 05 10款品种过评！涉及丽珠、方明药业等根据摩熵医药数据库统计，2025年8月11日至8月17日期间共有127项仿制药申报上市/申报临床获CDE承办，其中新注册分类上市申请受理号111项（包括化药3类，4类），新注册分类临床申请受理号8项（包括化药3类，4类），一致性评价申请8项。本周10个品种通过一致性评价（按受理号计16项），本周无品种视同通过一致性评价。本周有3项生物类似物注册申报动态，分别是惠升生物制药的司美格鲁肽注射液（按受理号计2项）、齐鲁制药的QL-2302注射液。本周过评/视同过评品种主要为系统用抗感染药物；过评/视同过评产品剂型主要为注射剂。截图来源：摩熵咨询周报本周注射用头孢噻肟钠品种过评/视同过评数量最多达5个，本周各品种过评/视同过评企业均为1家；各企业过评/视同过评品种数均为1种，本周过评/视同过评企业共包括湘北威尔曼制药股份有限公司、海南广升誉制药有限公司和武汉久安药业有限公司等10家企业。截图来源：摩熵咨询周报本周仅有盐酸米诺环素片1个品种为首次过评/视同过评。截图来源：摩熵咨询周报本周仅氟哌啶醇注射液1个品种的过评/视同过评达7家企业。截图来源：摩熵咨询周报摩熵咨询本期完整周报识别二维码领取下载 END 本文为原创文章，转载请留言获取授权近期热门资源获取中国临床试验趋势与国际多中心临床展望-202505 2024年医药企业综合实力排行榜-202505 中国带状疱疹疫苗行业分析报告-202505 2023H2-2024H1中国药品分析报告-202504 数据透视：中药创新药、经典验方、改良型新药、同名同方的申报、获批、销售情况-202503 2024年中国1类新药靶点白皮书-202503 中国AI医疗健康企业创新发展百强榜单-202502 解码护肤抗衰：消费偏好洞察与市场格局分析-202502 2024年FDA批准上市的新药分析报告-202501 小分子化药白皮书（上）-202501 2024年中国医疗健康投融资全景洞察报告-202501 2024年医保谈判及市场分析报告-202501 近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

临床申请孤儿药

2025-08-11

·国家药品监督管理局

2025年08月11日药品批准证明文件送达信息

2022年11月1日起，行政相对人可登录国家药品监督管理局政务服务门户的法人空间查看电子证照，按照相关提示自行打印。序号受理号药品名称申请人批准文号批准日期1CYHB2400439氨甲苯酸注射液湖南洞庭药业股份有限公司————2025年08月08日2CYHB2450232盐酸米诺环素片无锡凯夫制药有限公司————2025年08月08日3CYHB2450307注射用头孢噻肟钠湘北威尔曼制药股份有限公司国药准字H202581572025年08月07日4CYHB2450308注射用头孢噻肟钠湘北威尔曼制药股份有限公司————2025年08月07日5CYHB2450309注射用头孢噻肟钠湘北威尔曼制药股份有限公司————2025年08月07日6CYHB2450310注射用头孢噻肟钠湘北威尔曼制药股份有限公司————2025年08月07日7CYHB2450311注射用头孢噻肟钠湘北威尔曼制药股份有限公司————2025年08月07日8CYHB2450351注射用头孢呋辛钠海南广升誉制药有限公司————2025年08月07日9CYHB2450352注射用头孢呋辛钠海南广升誉制药有限公司————2025年08月07日10CYHB2450408注射用青霉素钠武汉久安药业有限公司————2025年08月07日11CYHB2450409注射用青霉素钠武汉久安药业有限公司————2025年08月07日12CYHB2450527盐酸哌罗匹隆片丽珠集团丽珠制药厂————2025年08月08日13CYHB2501455辛伐他汀片广东香山堂制药有限公司————2025年08月08日14CYHB2501456辛伐他汀片广东香山堂制药有限公司————2025年08月08日15CYHB2501467帕拉米韦注射液湖北美林药业有限公司————2025年08月08日16CYHB2501472注射用头孢唑肟钠山东二叶制药有限公司————2025年08月08日17CYHB2501473注射用头孢唑肟钠山东二叶制药有限公司————2025年08月08日18CYHB2501474注射用头孢唑肟钠山东二叶制药有限公司————2025年08月08日19CYZB2500317双蚁祛湿通络胶囊广西双蚁药业有限公司————2025年08月07日20CYZB2500620坤复康片陕西康惠制药股份有限公司————2025年08月06日21CYZB2500621盆炎净胶囊陕西康惠制药股份有限公司————2025年08月06日22CYZB2500634金鳝消渴颗粒贵州汉方药业有限公司————2025年08月06日23CYZB2500734润肠胶囊广州琥瑞医药科技发展有限公司————2025年08月06日24CYZB2500832乙肝健片(A、B)甘肃佛阁藏药有限公司————2025年08月06日25CYZB2500833乙肝健片甘肃佛阁藏药有限公司————2025年08月06日26CYZB2500864藿香正气胶囊山西黄河中药有限公司————2025年08月06日27CYZB2500866养胃舒软胶囊山西黄河中药有限公司————2025年08月06日28CYZB2500870复方苦木消炎片葵花药业集团湖北武当有限公司————2025年08月06日29CYZB2500923竹叶椒片兰州佛慈制药股份有限公司————2025年08月06日30CYZB2500961复方土槿皮酊福州海王金象中药制药有限公司————2025年08月07日31CYZB2500987健胃止疼五味胶囊乌兰浩特中蒙制药有限公司————2025年08月06日32CYZB2501025熊胆胶囊广东华南药业集团有限公司————2025年08月07日33CYZB2501031腰痛片陕西盘龙药业集团股份有限公司————2025年08月07日34CYZB2501033杞菊地黄胶囊陕西盘龙药业集团股份有限公司————2025年08月07日35CYZB2501036骨松宝片陕西盘龙药业集团股份有限公司————2025年08月07日36CYZB2501037接骨续筋片陕西盘龙药业集团股份有限公司————2025年08月07日37CYZB2501462银花感冒颗粒江西青峰药业有限公司————2025年08月06日38CYZB2501463益母草颗粒江西青峰药业有限公司————2025年08月06日39CYZB2501465肾石通颗粒江西青峰药业有限公司————2025年08月06日40CYZB2501466胃灵颗粒江西青峰药业有限公司————2025年08月06日41CYZB2501475排石利胆颗粒江西青峰药业有限公司————2025年08月06日42CYZB2501476陆英颗粒江西青峰药业有限公司————2025年08月06日43CYZB2501477宫炎康颗粒江西青峰药业有限公司————2025年08月06日44CYZB2501478阿归养血颗粒江西青峰药业有限公司————2025年08月06日45JTH2500110阿法骨化醇青松（天津）制药有限公司————2025年08月08日46JTH2500115依维莫司片泊诺（天津）创新医药研究有限公司————2025年08月08日47JTH2500116玛巴洛沙韦片上海罗氏制药有限公司————2025年08月08日48JYHB2400511富马酸贝达喹啉片西安杨森制药有限公司————2025年08月08日49JYHB2500211注射用盐酸依拉环素云顶新耀医药科技有限公司————2025年08月08日

申请上市临床申请核酸药物

2025-08-07

·PipelineReview

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

BERKELEY HEIGHTS, NJ, USA I August 07, 2025 I CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC (“Melinta”), a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced a definitive agreement for CorMedix to acquire Melinta. The selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of MINOCIN ® and REZZAYO™. The proposed acquisition will expand CorMedix’s team and commercial platform, and increase the commercial portfolio with six marketed, highly differentiated, hospital- and clinic-focused infectious disease products, including REZZAYO™ (rezafungin for injection), MINOCIN ® (minocycline) for Injection, VABOMERE ® (meropenem and vaborbactam), KIMYRSA ® (oritavancin), ORBACTIV™ (oritavancin), BAXDELA ® (delafloxacin), and an additional well-established cardiovascular product, TOPROL-XL ® (metoprolol succinate). REZZAYO™ is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation. The completion of the Phase III study for REZZAYO™ is expected in 1H 2026. “This acquisition is a transformational step in the evolution of CorMedix, providing an attractive revenue base of highly synergistic assets, as well as multiple opportunities to drive future growth. We are excited to acquire Melinta, which enables us to expand our product portfolio in the hospital space while delivering therapies to patients with high unmet need,” said Joseph Todisco, CEO of CorMedix Inc. “I would like to congratulate Christine Ann Miller, Melinta Therapeutics President & CEO, on building a high-performing organization. The combination with Melinta creates a formidable and diversified specialty platform with a deep and experienced team in the hospital acute care and infectious disease arena. This transaction reflects the type of high-impact, cash-flow generating opportunities we are targeting and strengthens our position to further expand, as we strive to create shareholder value through both organic growth and additional acquisitions in the future.” “The synergistic combination of Melinta and CorMedix represents an exciting new chapter in our company’s evolution,” said Christine Ann Miller, President and CEO of Melinta Therapeutics. “Over the past five years, we have built a robust commercial infrastructure with a high-performing team, deep expertise, and relationships within the hospital and acute care ecosystem, while achieving significant revenue growth and sustained profitability. CorMedix recognizes not just our innovative therapies, but the exceptional capabilities of our organization. I’m confident that Melinta’s commercial excellence and proven track record will augment CorMedix’s team and track record of operational execution and success, to create an even stronger platform for future growth.” Strategic and Financial Benefits Terms and Financing Under the terms of the agreement, which has been approved by the CorMedix and Melinta Board of Directors respectively, CorMedix will pay $300 million in upfront consideration, comprised of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders of Deerfield Management Company, L.P. (“Deerfield”). The cash consideration will be funded by a combination of CorMedix’s existing cash on hand and the proceeds of a $150 million convertible debt financing with high quality healthcare focused institutional investors, including Deerfield, the terms of which will be described in a Current Report on Form 8-K to be filed by the Company today. The agreement contains an additional regulatory milestone of up to $25 million (payable in cash or shares at CorMedix’s election) for the FDA approval of the expanded indication of REZZAYO™ for prophylaxis of invasive fungal infections in adults undergoing allogeneic blood and marrow transplantation, if this milestone event is achieved by June 30, 2029. Furthermore, the agreement includes tiered royalties on REZZAYO™ U.S. net sales and low-single-digit royalties on MINOCIN ® U.S. net sales. The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the ‘HSR Act’). The Company expects the transaction to close as early as September 1, 2025. Full Year Financial Guidance Advisors Moelis & Company LLC is acting as exclusive financial advisor for CorMedix in connection with the acquisition of Melinta and sole placement agent for convertible debt financing. Willkie Farr & Gallagher LLP is acting as legal advisor to CorMedix in connection with the acquisition of Melinta and the convertible debt financing. RBC Capital Markets is acting as a financial advisor to CorMedix in connection with the convertible debt financing. Goodwin Procter LLP is acting as a legal advisor to Moelis & Company LLC for the convertible debt financing. Conference Call and Webcast Information Management will host a conference call and a live webcast today, August 7, 2025, at 8:30 a.m. ET, to discuss the transaction and CorMedix’s second quarter 2025 financial results. The conference call can be accessed by dialing 1-844-676-2922 from the United States or 1-412-634-6840 internationally. The live webcast will be accessible in the “ Presentations & Events ” section of the CorMedix Investor Relations website or using the following Webcast Link . About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath ® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath ® in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath ® as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com . About Melinta Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: MINOCIN ® (minocycline), REZZAYO™ (rezafungin), VABOMERE ® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), and TOPROL-XL ® (metoprolol succinate). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, visit www.melinta.com . SOURCE: CorMedix

上市批准临床3期并购引进/卖出

100 项与盐酸米诺环素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00850	盐酸米诺环素	J01AA08 A01AB23	DB01017

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
玫瑰痤疮	美国	Journey Medical Corp.	2020-05-28
寻常痤疮	美国	Bausch Health US LLC	2006-05-08
炭疽	日本	Pfizer Japan, Inc.	2002-03-06
感染	中国	海口市制药厂有限公司	1992-01-01
地方性斑疹伤寒	日本	Pfizer Japan, Inc.	1989-09-01
鹦鹉热	日本	Pfizer Japan, Inc.	1985-11-05
急性支气管炎	日本	Pfizer Japan, Inc.	1979-04-20
细菌性阴道炎	日本	Pfizer Japan, Inc.	1979-04-20
膀胱炎	日本	Pfizer Japan, Inc.	1979-04-20
泪囊炎	日本	Pfizer Japan, Inc.	1979-04-20
附睾炎	日本	Pfizer Japan, Inc.	1979-04-20
淋病	日本	Pfizer Japan, Inc.	1979-04-20
睑腺炎	日本	Pfizer Japan, Inc.	1979-04-20
感染性肠炎	日本	Pfizer Japan, Inc.	1979-04-20
子宫内感染	日本	Pfizer Japan, Inc.	1979-04-20
颌骨炎症	日本	Pfizer Japan, Inc.	1979-04-20
喉炎	日本	Pfizer Japan, Inc.	1979-04-20
肺脓肿	日本	Pfizer Japan, Inc.	1979-04-20
淋巴结炎	日本	Pfizer Japan, Inc.	1979-04-20
乳腺炎	日本	Pfizer Japan, Inc.	1979-04-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
种植体周围炎	临床3期	美国	OraPharma, Inc.	2012-04-01
种植体周围炎	临床3期	德国	OraPharma, Inc.	2012-04-01
种植体周围炎	临床3期	瑞典	OraPharma, Inc.	2012-04-01
种植体周围炎	临床3期	英国	OraPharma, Inc.	2012-04-01
慢性牙周炎	临床3期	美国	Sunstar Americas, Inc.	2006-01-01
侵袭性牙周炎	临床3期	美国	OraPharma, Inc.	2004-01-01
脓疱疮	临床2期	以色列	VYNE Therapeutics, Inc.	2010-08-01
肌萎缩侧索硬化	临床2期	美国	Pfizer Inc.	2006-07-01
急性肾损伤	临床1期	德国	Rempex Pharmaceuticals, Inc.	2017-05-29
过敏性皮肤反应	临床1期	-	VYNE Therapeutics, Inc.	2016-09-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Phase II Trial Evaluating Minocycline for Geographic Atrophy (Pubmed \| Ophthalmol Sci)	临床2期	地图样萎缩	30	Minocycline 100 mg	齋齋衊鬱糧淵餘膚膚鹽(壓鑰構繭窪鏇觸壓壓壓) = 醖簾淵艱獵糧鬱鹹構觸廠衊鹹鬱夢艱膚淵願選 (餘艱蓋選夢鏇襯鹽願構, 0.85) 更多	不佳	2025-09-01
NCT02213575 (CTgov)	临床2期	高血压	5	Minocycline (Minocycline Treatment Group)	鹽夢衊願顧簾遞積築衊(糧繭憲簾積鏇淵構鹹築) = 憲窪獵夢窪觸餘鏇膚壓艱蓋艱憲築壓醖醖選網 (鏇衊築齋壓鏇膚鬱簾艱, 0.0292) 更多	-	2025-07-01
				minocycline (Control)	鏇範積願鬱獵願願廠夢(齋積糧廠觸獵醖齋觸襯) = 衊衊積膚夢選網繭壓簾願鏇遞製顧遞艱壓製衊 (繭糧觸繭憲網窪構膚糧, 鹽廠顧膚網築鹹憲衊獵 ~ 憲鹹艱遞蓋願夢願網繭) 更多
NCT05343455 \| NCT05296629 (MVOR-2, Company_Website) 人工标引	临床3期	玫瑰痤疮	653	Emrosi (MVOR-1)	顧鏇鑰窪壓製壓構襯窪(淵襯鏇繭獵淵膚鏇鏇夢) = 鬱醖蓋鬱餘簾艱繭醖襯選願網選繭獵醖製餘顧 (餘醖簾願鹹鹹遞範獵獵 ) 更多	积极	2025-06-20
				Doxycycline (MVOR-1)	顧鏇鑰窪壓製壓構襯窪(淵襯鏇繭獵淵膚鏇鏇夢) = 製糧鹽獵觸衊醖製構選選願網選繭獵醖製餘顧 (餘醖簾願鹹鹹遞範獵獵 ) 更多
NCT03106740 (IGNITE, CTgov)	临床2期	腰痛 \| 急性腰痛 \| 慢性疼痛 ... 更多	60	Magnetic Resonance-Positron Emission Tomography Imaging+Minocycline Hydrochloride 100mg Capsule (Minocycline Arm)	鏇製鬱鬱觸餘繭獵網糧(積憲鑰憲鹹醖鹽製艱艱) = 夢蓋窪襯簾觸夢觸壓網鏇糧壓選鏇夢遞齋築廠 (網顧艱膚選醖築鹹鏇選, 0.051) 更多	-	2025-05-11
				Magnetic Resonance-Positron Emission Tomography Imaging (Placebo Arm)	鏇製鬱鬱觸餘繭獵網糧(積憲鑰憲鹹醖鹽製艱艱) = 簾積壓憲餘網鑰鬱糧窪鏇糧壓選鏇夢遞齋築廠 (網顧艱膚選醖築鹹鏇選, 0.056) 更多
MVOR-1 and MVOR-2 (Pubmed \| JAMA Dermatol)	临床3期	玫瑰痤疮	653	DFD-29 40 mg	衊選鏇遞積壓製糧膚選(壓衊餘醖齋顧網餘憲顧) = 4 of 121 (3.3%), 3 of 116 (2.6%), and 4 of 76 (5.3%) in MVOR-1 and 7 of 122 (5.7%), 8 of 121 (6.6%), and 5 of 82 (6.1%) in MVOR-2 壓衊範憲窪鹽鹽齋網願 (鏇願窪鹹夢蓋遞鏇淵餘 ) 更多	积极	2025-05-01
				Doxycycline 40 mg
NCT02203552 (CTgov)	临床2期	复发性乳腺癌 \| 抑郁症 \| 焦虑症 ... 更多	56	laboratory biomarker analysis+minocycline hydrochloride (Arm I (Minocycline Hydrochloride))	齋願繭齋壓鹹積艱製鏇(衊醖鬱遞鬱襯遞廠鏇鏇) = 膚壓壓衊積憲鏇淵夢製憲衊範齋願繭壓淵醖襯 (鑰範選醖壓顧顧鑰廠齋, 廠壓積糧範製網選觸觸 ~ 獵廠夢鑰蓋網壓遞製襯) 更多	-	2025-01-08
				placebo (Arm II (Placebo))	齋願繭齋壓鹹積艱製鏇(衊醖鬱遞鬱襯遞廠鏇鏇) = 艱簾餘夢鬱夢網築膚餘憲衊範齋願繭壓淵醖襯 (鑰範選醖壓顧顧鑰廠齋, 艱獵簾網簾網繭餘顧遞 ~ 願廠簾選鹹淵鑰廠觸鹹) 更多
NCT05296629 (MVOR-1, CTgov)	临床3期	玫瑰痤疮	323	DFD-29 (DFD-29)	壓淵壓鬱衊構淵顧鏇艱 = 築糧觸積餘窪襯願窪憲襯鹽醖鑰廠鬱窪築顧糧 (夢築衊顧繭夢鹹壓網夢, 觸夢窪糧製醖淵廠積膚 ~ 築廠鹽廠築齋憲獵窪醖) 更多	-	2024-12-03
				Placebo (Placebo)	壓淵壓鬱衊構淵顧鏇艱 = 糧鹽鏇築範積觸蓋鹽鬱襯鹽醖鑰廠鬱窪築顧糧 (夢築衊顧繭夢鹹壓網夢, 憲襯鬱製鏇淵獵憲夢糧 ~ 觸夢積衊選鹹範糧繭簾) 更多
NCT05343455 (MVOR-2, CTgov)	临床3期	玫瑰痤疮	330	DFD-29 (DFD-29)	憲齋鹹鏇鑰窪構襯襯糧 = 選襯蓋壓齋簾遞淵齋網簾鹽醖襯艱廠構醖廠觸 (網觸齋鑰鹽壓範簾齋網, 構製築獵夢構繭襯夢願 ~ 艱網遞獵築壓鬱鑰襯獵) 更多	-	2024-12-03
				Placebo (Placebo)	憲齋鹹鏇鑰窪構襯襯糧 = 鹹鬱廠窪鏇獵鬱鹹糧齋簾鹽醖襯艱廠構醖廠觸 (網觸齋鑰鹽壓範簾齋網, 壓餘簾鑰壓鬱夢齋遞衊 ~ 簾獵憲願觸積蓋蓋糧範) 更多
NCT05343455 \| NCT05296629 (MVOR-2, FDA_CDER) 人工标引	临床3期	玫瑰痤疮	653	EMROSI (MVOR-1)	遞齋簾餘鹽鹽鹹夢構獵(衊鬱窪襯製艱襯夢鏇範) = 夢鬱鹽願憲網衊鹽襯簾構簾襯夢範簾網繭網鑰 (繭夢鹹艱製衊築糧窪鑰 ) 更多	积极	2024-11-13
				Doxycycline (MVOR-1)	遞齋簾餘鹽鹽鹹夢構獵(衊鬱窪襯製艱襯夢鏇範) = 築簾齋獵鑰襯糧窪糧繭構簾襯夢範簾網繭網鑰 (繭夢鹹艱製衊築糧窪鑰 ) 更多
CTR20211291 (NEWS) 人工标引	临床3期	寻常痤疮	-	外用4%米诺环素泡沫剂	構糧鑰醖膚壓壓夢願鏇(襯觸鹽簾餘糧窪齋鏇憲): P-Value = <0.001 达到更多	积极	2024-07-30
				Placebo